ReviewNPJ breast cancer2026
Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.
Review in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as an important single-agent targeted therapeutic option for a subpopulation of breast cancer patients. While PARPi combinations have shown synergy in the pre-clinical setting, concomitant regimens have shown limited clinical benefit. Optimizing treatment schedules is therefore needed to improve outcomes. Sequential dosing of PARPi with cytotoxic, targeted, or immune therapies can enhance efficacy by sustaining DNA damage, suppressing DNA repair, and modulating the immune response. This approach also decreases toxicity by exploiting differences in replication stress between normal and cancer cells. Here, we discuss the rationale for improved efficacy and enhanced tolerability with sequential PARPi approaches, supported by pre-clinical and clinical evidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.